Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Rating of “Moderate Buy” by Brokerages

Pharvaris N.V. (NASDAQ:PHVS) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $51.0769.

PHVS has been the subject of a number of recent analyst reports. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a report on Thursday. Royal Bank Of Canada lifted their target price on Pharvaris from $51.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday. Citizens Jmp boosted their price target on Pharvaris from $74.00 to $75.00 and gave the stock a “market outperform” rating in a research report on Thursday. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Wells Fargo & Company started coverage on Pharvaris in a report on Wednesday, July 15th. They set an “overweight” rating and a $55.00 price target on the stock.

Pharvaris Price Performance

Shares of NASDAQ:PHVS opened at $35.14 on Monday. The company’s 50-day moving average price is $33.71 and its 200 day moving average price is $30.11. The company has a market cap of $2.30 billion, a PE ratio of -11.52 and a beta of -2.31. Pharvaris has a fifty-two week low of $20.65 and a fifty-two week high of $36.93.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, equities analysts anticipate that Pharvaris will post -3.08 EPS for the current year.

Insider Activity at Pharvaris

In related news, CFO David W. Nassif sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $30.31, for a total transaction of $303,100.00. Following the sale, the chief financial officer owned 120,300 shares of the company’s stock, valued at $3,646,293. The trade was a 7.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,968.88. Following the transaction, the director directly owned 315,167 shares of the company’s stock, valued at approximately $11,185,276.83. The trade was a 8.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 156,030 shares of company stock worth $5,304,914 in the last three months.

Institutional Trading of Pharvaris

Several institutional investors have recently modified their holdings of PHVS. Quantbot Technologies LP bought a new position in Pharvaris during the second quarter valued at about $41,000. GF Fund Management CO. LTD. bought a new stake in Pharvaris in the fourth quarter worth about $35,000. CoreCap Advisors LLC acquired a new stake in Pharvaris in the 2nd quarter valued at about $93,000. Barclays PLC acquired a new stake in Pharvaris in the 4th quarter valued at about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Pharvaris during the 4th quarter valued at about $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.